Literature DB >> 29098318

[Wilson's disease : What has been confirmed in diagnostic and therapy?]

E-D Pfister1.   

Abstract

Wilson's disease (WD) is a rare autosomal recessive disorder characterized by abnormal copper accumulation. Presenting a broad variety of phenotypes and, thus, being a chameleon within the group of metabolic diseases, the manifold clinical symptoms of WD can include hepatologic, neurologic, and psychiatric manifestations. Early onset presentations in infancy and late-onset manifestations in adults older than 70 years of age have been described. If the typical laboratory blood test values are missing, the diagnosis of WD may be difficult and often involves a combination of different parameters. Novel test methods like the identification of the relative exchangeable copper have not been validated within a sufficient cohort of WD patients as of yet and therefore do not currently play a crucial role within the clinical setting. Consequently any patient with reasonable suspected diagnosis of WD needs to be presented to a (pediatric) gastroenterologist and/or (pediatric) neurologist. Different medical treatments including drugs such as copper chelating agents are commonly used in the clinical setting. Liver transplantation may be the ultima ratio in selected patients. Dietary changes involving a low copper diet play only a minor role. Due to the fact the use of tetrathiomolybdate is still not approved, the treatment of advanced and progressive neurologic symptoms remains a major challenge. In any case, life-long medical supervision and treatment governed by a specialist is absolutely essential. Early diagnosis and early and life-long treatment lead to better prognoses and do not negatively influence the overall life expectancy.

Entities:  

Keywords:  Chelating agents, copper; Liver transplantation; Penicillamine; Tetrathiomolybdate; Zinc

Mesh:

Substances:

Year:  2017        PMID: 29098318     DOI: 10.1007/s00108-017-0342-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  7 in total

1.  8th International Conference on Wilson Disease and Menkes Disease. Leipzig, Germany, April 16-18, 2001. Abstracts.

Authors: 
Journal:  Z Gastroenterol       Date:  2001-03       Impact factor: 2.000

2.  EASL Clinical Practice Guidelines: Wilson's disease.

Authors: 
Journal:  J Hepatol       Date:  2012-03       Impact factor: 25.083

3.  Diagnosis and treatment of Wilson disease: an update.

Authors:  Eve A Roberts; Michael L Schilsky
Journal:  Hepatology       Date:  2008-06       Impact factor: 17.425

4.  Wilson's disease in children: 37-year experience and revised King's score for liver transplantation.

Authors:  Anil Dhawan; Rachel M Taylor; Paul Cheeseman; Pamela De Silva; Leah Katsiyiannakis; Giorgina Mieli-Vergani
Journal:  Liver Transpl       Date:  2005-04       Impact factor: 5.799

5.  Long term results of liver transplantation for Wilson's disease: experience in France.

Authors:  Olivier Guillaud; Jérôme Dumortier; Rodolphe Sobesky; Dominique Debray; Philippe Wolf; Claire Vanlemmens; François Durand; Yvon Calmus; Christophe Duvoux; Sébastien Dharancy; Nassim Kamar; Karim Boudjema; Pierre Henri Bernard; Georges-Philippe Pageaux; Ephrem Salamé; Jean Gugenheim; Alain Lachaux; Dalila Habes; Sylvie Radenne; Jean Hardwigsen; Olivier Chazouillères; Jean-Marc Trocello; France Woimant; Philippe Ichai; Sophie Branchereau; Olivier Soubrane; Denis Castaing; Emmanuel Jacquemin; Didier Samuel; Jean-Charles Duclos-Vallée
Journal:  J Hepatol       Date:  2013-11-06       Impact factor: 25.083

6.  Wilson's disease: clinical presentation and use of prognostic index.

Authors:  H Nazer; R J Ede; A P Mowat; R Williams
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

Review 7.  Diagnosis and phenotypic classification of Wilson disease.

Authors:  Peter Ferenci; Karel Caca; Georgios Loudianos; Georgina Mieli-Vergani; Stuart Tanner; Irmin Sternlieb; Michael Schilsky; Diane Cox; Frieder Berr
Journal:  Liver Int       Date:  2003-06       Impact factor: 5.828

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.